

### **REMARKS/ARGUMENTS**

Restriction to one of the following inventions is required under 35 U.S.C. §121:

- I. Claims 1-8, drawn to an isolated nucleic acid, a vector, a host cell, and a process of producing a PRO polypeptide, classified in class 536, subclasses 23.5; class 435, subclass 320.1, 325, and 69.1.
- II. Claims 9-11, 14-17 (in part), drawn to an isolated polypeptide, classified in class 530, subclass 350.
- III. Claims 12, 13, 14-17 (in part), drawn to an antibody, classified in class 530, subclass 387.9.
- IV. Claims 18 and 19 (in part), drawn to a method of treating an immune related disorder, comprising administering to said mammal a therapeutically effective amount of a polypeptide, class 514, subclass 12.
- V. Claims 14-17 (in part), drawn to a composition comprising an agonist of a polypeptide, classification depend upon the structure of the agonist.
- VI. Claims 14-17 (in part), drawn to a composition comprising an antagonist of a polypeptide, classification depend upon the structure of the antagonist.
- VII. Claims 18 and 19 (in part), drawn to a method of treating an immune related disorder, comprising administering to said mammal a therapeutically effective amount of an antibody, class 424, subclass 130.1.
- VIII. Claims 18 and 19 (in part), drawn to a method of treating an immune related disorder, comprising administering to said mammal a therapeutically effective amount of an agonist, classification depend upon the structure of the agonist.
- IX. Claims 18 and 19 (in part), drawn to a method of treating an immune related disorder, comprising administering to said mammal a therapeutically effective amount of an agonist, classification depend upon the structure of the antagonist.
- X. Claims 20 and 22, drawn to a method for determining the presence of a PRO polypeptide, classified in class 435, subclass 7.1.
- XI. Claims 21 and 28, drawn to a method of diagnosing an immune related disease comprising detecting the level of expression of a gene encoding a PRO polypeptide, classified in class 435, subclass 6.
- XII. Claims 23 and 26, drawn to a method of identifying a compound that inhibits the activity of a PRO polypeptide, classified in class 435, subclass 4.

- XIII. Claims 24 and 25, drawn to a method of identifying a compound that inhibits the expression of a gene encoding a PRO polypeptide, classified in class 435, subclass 6.
- XIV. Claim 26, drawn to a method of stimulating an immune response in a mammal comprising administering to said mammal an effective amount of a PRO polypeptide, classified in class 514, subclass 12.

In a Response filed on April 16, 2008, Applicants elected Groups III with traverse, Claims 12, 13, 14-17 (in part), drawn to an antibody which specifically binds to a polypeptide according to claim 10 and composition thereof. Applicants further elected SEQ ID NO:147 (nucleic acid) and 148 (polypeptide) (PRO1265;DNA304827) for further prosecution. Applicants submit that, due to a typographical error, SEQ ID NO:147 in fact should be SEQ ID NO:43 while SEQ ID NO:148 should be SEQ ID NO:44. During a telephone communication with the Examiner dated May 22, 2008, the Examiner suggested that Applicants submit a supplemental response to correct such an error. Applicants hereby submit the present Supplemental Response and Amendment following the Examiner's suggestion.


Applicants have amended Claim 12 to recite the correct SEQ ID NOs. The amendments are fully supported by the specification and claims originally filed and do not introduce any new matter. Applicants reserve the right to pursue the canceled subject matters in a continuation, continuation-in-part, or a divisional application. Claims 12-17 are pending after the amendment. Applicants respectfully request that the Examiner consider the amendment.

**CONCLUSION**

In conclusion, the present application is believed to be in *prima facie* condition for allowance, and an early action to that effect is respectfully solicited. Should there be any further issues outstanding, the Examiner is invited to contact the undersigned attorney at the telephone number shown below. Please charge any additional fees, including fees for additional extension of time, or credit overpayment to Deposit Account No. **07-1700** (referencing Attorney's Docket No. **GNE-0261 R1**).

Respectfully submitted,

Dated: June 10, 2008

By:   
Panpan Gao (Reg. No. 43,626)

**GOODWIN PROCTER LLP**  
135 Commonwealth Drive  
Menlo Park, California 94025  
Telephone: (650) 752-3100  
Facsimile: (650) 853-1038